Search Results 291-300 of 18476 for prednisone

1. Study of Oraxol and Pembrolizumab in Subjects with Advanced Solid Tumors - Mayo Clinic

   of prednisone or its equivalent. - Vaccinated with live, attenuated vaccines within 28 days of the first dose of the study drug - Active or prior documented ...

2. A Study To Evaluate The Effectiveness, Safety And Tolerability Of PF-06823859 In Adults With Moderate-to-Severe Dermatomyositis - Mayo Clinic

   Investigator site staff or members of their family. · Acute and Chronic present medical conditions. · Intake of greater than 15 mg of prednisone or equivalent per ...

3. A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants - Mayo Clinic

   ... 1 of Cycle 1; Current use of systemic corticosteroids greater than (>) 20 mg prednisone per day (or equivalent), or prior anti-cancer therapy to include ...

4. A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects with Ulcerative Colitis - Mayo Clinic

   Steroids (i.e., prednisone/budesonide/budesonide MMX); Immunosuppressant (i.e., methotrexate/azathioprine/6-mercaptopurine); Other immunosuppressant (i.e. ...

5. A Study of Fresolimumab in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS) - Mayo Clinic

   Participation eligibility · The patient has FSGS which in the Investigator's opinion is secondary to another condition · The patient has been taking prednisone at ...

6. Belimumab In Remission Of VASculitis - Clinical Trials

   Remission is defined as a Birmingham Vasculitis Activity (BVAS) score of 0 and receiving less than 10 mg/day of oral prednisone (or equivalent) on 2 consecutive ...

7. Ceftolozane/Tazobactam In Pediatric Patients With Nosocomial Pneumonia - Mayo Clinic

   ... prednisone for participants ≤ 20 kg, or > 40 mg of prednisone per day for participants > 20 kg, administered continuously for more than 14 days in the 30 ...

8. A Study to Evaluate Itacitinib for Low Risk Graft-vs-Host Disease (GVHD) - Mayo Clinic

   Patients receiving corticosteroids >10 mg/day prednisone (or other steroid equivalent) for any indication within 7 days before the onset of acute GVHD ...

9. Dysfunction of Mesenchymal Stem/Stromal Cells Induced by Obesity - Mayo Clinic

   Therapeutic doses of immunosuppressive drugs (including calcineurin inhibitors and prednisone (> 10 mg/day). Senolytic supplements. Subjects on therapeutic ...

10. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and Combined with Chemotherapy or Tislelizumab to Treat Patients with Metastatic Solid Tumors - Mayo Clinic

    ... prednisone or equivalent) for at least 4 weeks prior to the first dose of study drug. Evidence of severe or uncontrolled systemic diseases, congestive heart ...